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Abstract
Background Postoperative delirium (POD) is a frequent and serious complication after surgery. Evidence of a relationship 
between anticholinergic medication and the development of delirium is inconclusive, but studies on POD are rare.
Objectives The objective of this study was to evaluate the anticholinergic load of preoperative medication in older adult 
patients and its association with the development of POD.
Methods This investigation was part of the European BioCog project (http://www.bioco g.eu), a prospective multicenter 
observational study in older adult surgical patients (ClinicalTrials.gov identifier: NCT02265263, 15 October 2014). Patients 
with a Mini–Mental State Examination score ≤ 23 points were excluded. POD was assessed up to 7 days after surgery 
using the Nursing Delirium Screening Scale, Confusion Assessment Method and a patient chart review. The preoperative 
anticholinergic load was calculated using the Anticholinergic Drug Scale (ADS), the Anticholinergic Risk Scale (ARS) and 
the Anticholinergic Cognitive Burden Scale (ACBS), and associations with POD were analyzed using logistic regression 
analysis adjusting for age, comorbidities, duration of anesthesia and number of drugs used.
Results In total, 837 participants were included for analysis, and 165 patients (19.7%) fulfilled the criteria of POD. After 
adjusting for confounders, we found no association between preoperative anticholinergic load and the development of 
POD (ADS [points] odds ratio [OR] 0.928; 95% confidence interval [CI] 0.749–1.150; ARS [points] OR 0.832; 95% CI 
0.564–1.227; ACBS [points] OR 1.045; 95% CI 0.842–1.296).
Conclusion This study found no association between the anticholinergic load of drugs used preoperatively and the develop-
ment of POD in older adult patients without severe preexisting cognitive impairment. Future analyses should examine the 
influence of intra- and postoperative administration of anticholinergic drugs as well as dosages of and interactions between 
medications.
 * Claudia D. Spies 
 claudia.spies@charite.de
Extended author information available on the last page of the article
1 Introduction
Postoperative delirium (POD) is a common and serious 
neurocognitive complication, presenting as an acute dis-
turbance in attention and cognition that is not based on a 
preexisting neurocognitive disorder [1, 2]. POD is associ-
ated with increased length of hospitalization [3], impaired 
functional status [4], long-term cognitive impairments [5–7] 
and increased short-term and long-term mortality [1]. The 
incidence of POD is dependent on predisposing risk factors 
(e.g., age, cognitive impairment, comorbidity or impaired 
functional status) and precipitating risk factors (e.g., major 
Key Points 
Depending on the scale used, the anticholinergic load of 
long-term medications varied considerably.
This study found no association between the anticho-
linergic load (according to Anticholinergic Drug Scale, 
Anticholinergic Risk Scale and Anticholinergic Cogni-
tive Burden Scale) of preoperative long-term medication 
and the development of postoperative delirium in older 
adult patients.
Future analyses should examine the influence of intra- 
and postoperative administration of anticholinergic drugs 
as well as dosages of and interactions between medica-
tions.
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BioCog study is to establish biomarker panels for risk and 
clinical outcome prediction of POD and postoperative cogni-
tive dysfunction [22]. The study was approved by the local 
ethics committees (ref.: EA2/092/14 and 14-469) and con-
ducted in accordance with the declaration of Helsinki (Clin-
icalTrials.gov: NCT02265263). Written informed consent 
was obtained from each patient, and all local data privacy 
regulations were followed.
We included patients who were aged ≥ 65 years, of Euro-
pean descent, undergoing elective surgery with an expected 
surgical duration ≥ 60 min, and able and willing to provide 
informed consent and undergo magnetic resonance imaging. 
Patients with a Mini–Mental State Examination score ≤ 23 
points were excluded, as well as those who were homeless 
or could not be reached by phone or postal services for fol-
low-up examinations. In addition, we excluded participants 
enrolled in any concurrent prospective interventional clinical 
study during their hospital stay, those who were accommo-
dated in an institution because of an official or judicial order 
and those with conditions limiting the conduction of the 
neurocognitive testing, such as neuropsychiatric conditions, 
hearing impairment or language barriers.
2.2  Baseline Measurements
The following baseline and perioperative measurements 
were collected to describe study population: age, sex, physi-
cal status according to the American Society of Anesthe-
siologists (ASA PS), Charlson Comorbidity Index (CCI) 
[23], duration of anesthesia and site of surgery (intratho-
racic/intraabdominal/intrapelvic, peripheral and intracranial 
operations).
2.3  Postoperative Delirium
POD was defined according to Diagnostic and Statisti-
cal Manual of Mental Disorders 5th Edition criteria [24]. 
Patients were considered delirious if they had ≥ 2 cumula-
tive points on the Nursing Delirium Screening Scale and/or 
a positive Confusion Assessment Method (CAM) score and/
or a positive CAM for the Intensive Care Unit (CAM-ICU) 
score and/or descriptions of delirium on patient chart review 
(e.g., confused, agitated, drowsy, disorientated, delirious, or 
received antipsychotic therapy for delirium).
Delirium screening commenced in the recovery room 
and was repeated twice a day, at 08:00 and 19:00 (± 1 h), 
up to 7 days after surgery. Delirium assessment was con-
ducted independently of the routine hospital procedures by 
a research team that was trained and supervised by psy-
chiatrists and other delirium experts.
surgery) [1, 8]. Older adult patients are particularly at risk 
of developing POD. The number of older adults undergoing 
surgery is rising, and demographic changes indicate that this 
trend will continue. Preoperative optimization, particularly 
the adaptation of long-term medication, plays an important 
role in the prevention of delirium.
Given the accumulation of comorbidities in older adults, 
these patients are more likely to be subject to polypharmacy 
and inappropriate prescriptions, and anticholinergic adverse 
effects are frequently described in the literature [9]. Cholin-
ergic neurotransmission plays an important role in cognitive 
performance [10–13], and associations between anticholin-
ergic adverse effects and the development of dementia or 
other cognitive disorders have been described [14, 15]. Few 
studies have evaluated the relationship between anticholin-
ergic medication and the development of delirium. A recent 
investigation described an association between anticho-
linergic burden, according to Anticholinergic Drug Scale 
(ADS) score [16], and the development of POD in older 
patients with cancer [17]. Overall, studies investigating an 
association with POD are rare, and the evidence regarding 
anticholinergic medication is so far inconclusive. Over the 
years, a number of scales have been developed to simply and 
efficiently map the anticholinergic burden of drugs, although 
reviews on this topic [18, 19] have criticized that “variation 
exists in scale development, in the selection of anticholin-
ergic drugs, and [in] the evaluation of their anticholinergic 
load” [19].
Preoperative adaptation of long-term medication, espe-
cially anticholinergic drugs, would be a feasible option to 
improve treatment. However, an immediate prerequisite 
for this is the valid mapping of the anticholinergic load of 
medications.
The aim of this analysis was to evaluate the preoperative 
long-term medication of older adult patients according to 
the most cited anticholinergic scales (ADS, Anticholinergic 
Risk Scale [ARS] [20] and the Anticholinergic Cognitive 
Burden Scale [ACBS] [21]) and to investigate an association 
between scores on these scales and the development of POD.
2  Methods
2.1  Study Design and Population
This investigation was performed as part of the BioCog 
project (http://www.bioco g.eu), a prospective multicenter 
observational study conducted at the Charité-Universitäts-
medizin Berlin, Department of Anesthesiology and Opera-
tive Intensive Care Medicine, Berlin, Germany, and the 
University Medical Center Utrecht, Department of Inten-
sive Care Medicine, Utrecht, Netherlands. The goal of the 
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2.4  Anticholinergic Load
The preoperative anticholinergic load was calculated using 
the ADS [16], the ARS [20] and the ACBS [21], which 
are the most cited anticholinergic scales. These all assign 
a certain number of points to a drug, ranging from “0 
points” (no anticholinergic activity) to “3 points” (high-
est anticholinergic activity). An initial analysis merely 
determined the presence of any anticholinergic medica-
tion listed in each of the scales in the patient medication 
list. This was followed by an analysis considering the 
total number of points given for each scale. Long-term 
medication was determined during the preoperative anes-
thesia consultation by means of anamnesis or reviewing 
the patient’s medical record or medication prescriptions. 
Long-term medication included both prescription and 
over-the-counter medication taken regularly at the time 
of enrollment.
2.5  Statistical Analysis
Baseline characteristics were expressed as median and 25th 
quartile and 75th quartile, mean ± standard deviation (SD), 
or frequencies with percentages. Differences between the 
groups were tested using the Mann–Whitney U test or chi-
squared test. The associations between POD and anticho-
linergic burden (according to ADS, ARS and ACBS) were 
investigated via multivariable logistic regression analyses, 
adjusting for possible confounding variables selected a pri-
ori, including age, CCI, duration of anesthesia and number 
of long-term medications. No adjustments were made for 
multiple testing. All analyses were performed with SPSS 
Statistics, version 23 (IBM; Armonk, NY, USA) and in the R 
software environment (R Foundation for Statistical Comput-
ing, Vienna, Austria; 2017).
3  Results
A total of 1033 participants were enrolled in two study 
centers between October 2014 and April 2017. Accounting 
for early dropouts and missing data, 837 participants could 
be included in the analysis. Of these, 165 patients (19.7%) 
developed a POD (Fig. 1). Patients with POD were signifi-
cantly older, had higher ASA PS and CCI scores and longer 
duration of anesthesia. Group differences were also seen 
according to site of surgery. Surgery was most frequently 
Fig. 1  Flow chart of study 
participant selection. POD 
postoperative delirium
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performed on the musculoskeletal system and digestive tract 
(see Table S1 in the Electronic Supplementary Material). No 
sex differences were observed (see Table 1). 
In total, 23.8% (n = 199) of patients were taking medica-
tion with anticholinergic properties preoperatively according 
to the ADS, 7.2% (n = 60) according to the ARS and 28.7% 
(n = 240) according to the ACBS. The mean ± SD anticholin-
ergic load score was 0.4 ± 0.9 points for the ADS, 0.13 ± 0.5 
points for the ARS and 0.4 ± 0.8 points for the ACBS. In all 
three scales, amitriptyline was the most frequently prescribed 
level III agent. In levels I and II, the most frequently taken 
agents differed between the scales (Table 2 lists the most fre-
quently taken anticholinergic agents per score and level). There 
were no differences between subjects with and without POD 
in the distribution of the most frequently taken drugs per level 
of the anticholinergic scores. A preoperative adjustment of the 
anticholinergic medication was not routinely undertaken. 
A descriptive analysis showed no differences between 
patients with and without POD in regard to administration 
of anticholinergic medication according to ADS, ARS and 
ACBS or the total score of ADS, ARS or ACBS (Table 3). 
In addition, when considering confounding factors, anticho-
linergic load (according to ADS, ARS and ACBS) was not 
associated with the development of POD in the multivariable 
logistic regression analyses (ADS, odds ratio [OR] 0.955; 
95% confidence interval [CI] 0.621–1.468; ADS [points] 
OR 0.928; 95% CI 0.749–1.150; ARS OR 0.784; 95% CI 
0.376–1.635; ARS [points] OR 0.832; 95% CI 0.564–1.227; 
ACBS OR 1.132; 95% CI 0.762–1.681; ACBS [points] OR 
1.045; 95% CI 0.842–1.296). 
4  Discussion
In summary, we did not find an association between 
anticholinergic load (according to ADS, ARS and ACBS) 
and the development of POD. This investigation included 
patients undergoing elective surgery across a wide range 
of surgical disciplines, of which nearly 20% developed 
POD. This is in line with other cohorts and investigations 
[1].
Table 1  Patient characteristics (n = 837) for analysis of postoperative delirium
Data are expressed as median (25th quartile; 75th quartile) or as mean ± standard deviation except for categorical data, which are expressed as 
frequencies (percentages)
ASA PS American Society of Anesthesiologists physical status, POD postoperative delirium
p ≤ 0.05 was considered as statistically significant
a Mann–Whitney U test between patients with or without POD
b Chi-squared test between patients with or without POD
Characteristic POD (n = 165 [19.7%]) No POD (n = 672 [80.3%]) p-Value
Age (years) 74 (70; 77) 71 (68; 75) < 0.001a
Female sex 79 (47.9) 283 (42.1) 0.180 b
ASA PS
 1–2 77 (46.7) 463 (68.9) < 0.001b
 3–4 88 (53.3) 209 (31.1)
Charlson Comorbidity Index 1.86 ± 1.5 1.31 ± 1.5 < 0.001a
Duration of anesthesia (min) 306 (211; 473) 168 (105; 255) < 0.001a
Site of surgery
 Intracranial 2 (1.2) 8 (1.2)
 Intrathoracic/intraabdominal/intrapelvic 105 (63.6) 248 (36.9) < 0.001b
 Peripheral 58 (35.2) 416 (61.9)
Number of agents 5.41 ± 3.7 4.44 ± 3.8 0.002a
Table 2  Distribution of most frequently taken anticholinergic agents 
per score and level of preoperative long-term medication (n  =  837 
patients)
ACBS Anticholinergic Cognitive Burden Scale, ADS Anticholinergic 
Drug Scale, ARS Anticholinergic Risk Scale
Scale Level n Agent (% within level)
ADS I 248 Oxycodone (15%), prednisolone (13%), 
tramadol (11%)
II 8 Ranitidine (62%), carbamazepine 
(38%)
III 24 Amitriptyline (83%)
ARS I 38 Pramipexole (29%), mirtazapine (21%)
II 5 Loperamide (60%)
III 20 Amitriptyline (100%)
ACBS I 244 Metoprolol (68%)
II 15 Ipratropium bromide (80%)
III 26 Amitriptyline (77%)
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Cholinergic neurotransmission plays an important role 
in cognitive performance, and a leading hypothesis model 
explains the connection between anticholinergic effects 
and the pathogenesis of delirium [25]. van Gool et al. 
[25] hypothesized that cholinergic inhibition could sup-
press the formation of a vicious cycle where neuroinflam-
mation is maintained by the activation of microglia cells. 
He postulated that any dysfunction in cholinergic neuro-
transmission could hinder this mechanism and promote 
the development of delirium [25]. It is conceivable that 
anticholinergic adverse effects can promote the develop-
ment of delirium, as this has already been observed in 
different settings. For example, associations were reported 
between the anticholinergic load according to the ACBS 
and the development of delirium in acutely ill patients 
[26, 27], between the anticholinergic load according to the 
ARS and the development of delirium in frail older adults 
living in a nursing home [28], and between the increase in 
ARS score and development of delirium in palliative care 
inpatients [29].
However, our analysis could not confirm an association 
between anticholinergic load and the development of POD 
in older surgical patients. This is in line with a study inves-
tigating patients aged ≥ 65 years with hip fracture, which 
could not find an association between a high anticholinergic 
burden, according to a total score of at least 3 in the clini-
cian‐rated ADS, and the development of POD [30]. Further-
more, another study found no association between anticho-
linergic activity in serum or cerebrospinal fluid, determined 
according to a muscarinic radio receptor bioassay, and the 
development of POD [31].
Notably, our results are in contrast with the recently pub-
lished study on anticholinergic burden and development of 
POD in older patients with cancer [17], which found an asso-
ciation between anticholinergic burden (ADS) and develop-
ment of POD. Differing results may be explained by differing 
target populations (patients with cancer), and generalizability 
might have been limited by the national design, whereas Bio-
Cog was an international multicenter study. Furthermore, in 
the positive study, 16% of patients were using anticholiner-
gic medication preoperatively and the reported mean ADS 
score was 0.2 points, whereas preoperative use in our cohort 
reached 24% and the mean ADS score was 0.4 points. This 
can be primarily explained by the international design of the 
BioCog study. The patients treated at the Utrecht study center 
had significantly higher ADS scores and were significantly 
more frequently affected by anticholinergic load than the 
patients treated at the Berlin study center. Lastly, the incidence 
of POD in the positive study was low at 10%, which could 
be attributed to patient empowerment through intervention, 
whereas we observed an incidence of 20% in our cohort.
It must be noted that a well-known issue in the investiga-
tion of anticholinergic drugs is that an agent can be rated as 
having a different level of anticholinergic properties accord-
ing to the scale used. To deal with this, we calculated the 
anticholinergic load of the long-term medication using the 
three most comprehensive scales: ADS, ARS and ACBS. 
Nevertheless, each scale has advantages and disadvantages 
that must be taken into account. While the ADS has been 
validated by a laboratory chemical method showing an asso-
ciation with serum anticholinergic activity, there is no ref-
erence in the literature to the establishment of the scale or 
to the criteria utilized to assign drugs to the different scale 
levels [16]. Substantial methodological effort was used in 
the creation of the ARS. After a review of the 500 most 
commonly prescribed drugs, agents with known potential to 
cause anticholinergic adverse effects (AEs) were identified 
and associated with the dissociation constant for the cholin-
ergic receptor. A literature search regarding anticholinergic 
AEs was then conducted, all information was reviewed by 
independent assessors and the medication was classified 
accordingly [20]. The ARS was then validated using both 
Table 3  Anticholinergic load and postoperative delirium (n = 837 patients)
Data are expressed as mean ± standard deviation except for categorical data, which are expressed as frequencies (percentages)
ACBS Anticholinergic Cognitive Burden Scale, ADS Anticholinergic Drug Scale, ARS Anticholinergic Risk Scale, POD postoperative delirium
p ≤ 0.05 was considered as statistically significant
a Mann–Whitney U test between patients with or without POD
b Chi-squared test between patients with or without POD
Characteristic POD (n = 165 [19.7%]) No POD (n = 672 [80.3%]) p-Value
ADS (points) 0.45 ± 0.92 0.39 ± 0.86 0.484a
Anticholinergic medication according to the ADS 42 (25.5) 157 (23.4) 0.572b
ARS (points) 0.12 ± 0.50 0.13 ± 0.54 0.973a
Anticholinergic medication according to the ARS 12 (7.3) 48 (7.1) 0.954b
ACBS (points) 0.53 ± 0.97 0.39 ± 0.77 0.085a
Anticholinergic medication according to the ACBS 56 (33.9) 184 (27.4) 0.095b
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retrospective and prospective designs via associations with 
anticholinergic AEs [20]. ACBS was based on a literature 
review of anticholinergic activity and cognitive function in 
older patients. The identified drugs were then classified by 
an interdisciplinary team of experts [21]. The ACBS has not 
been formally validated.
Consequentially, it is not surprising that reported results 
differ according to the scale used, with not only total scores 
varying but also the overall prevalence of anticholinergic load. 
Despite these differences, the results were similar for all three 
scales, and no association with POD was observed, likely sup-
porting the validity of the results. However, we cannot rule out 
that the reason we found no association between anticholin-
ergic load and POD is that the anticholinergic load classifica-
tion is inappropriate in all three scales. It has been discussed 
that the intake of any anticholinergic drug or the number of 
anticholinergic drugs is not as decisive as the combination 
and subsequent interaction of certain anticholinergic agents 
[9]. In addition, it seems reasonable to consider the dosage of 
anticholinergic drugs. To our knowledge, the Drug Burden 
Index is the only scale that takes dosages into account [32]. 
The index is based on a mathematical formula that includes 
the anticholinergic and sedative effects of drugs. In contrast 
to other anticholinergic scales, there is no positive or nega-
tive list of drugs for the index. Instead, drugs are identified 
using local formulary, which vary between countries. Practi-
cal application requires the development of a local list from 
current approved product information [33]. This makes the 
practical application of this tool very difficult. Another inter-
esting investigation would be to determine whether patients 
benefit from preoperative adjustment of anticholinergic drugs 
in terms of developing POD, preferably employing a rand-
omized controlled trial design. Ultimately, the immediate pre-
requisite for the development of preventive strategies, in the 
sense of preoperative adaptation of long-term anticholinergic 
drugs, remains the valid mapping of the anticholinergic load 
of the substance.
It is conceivable that factors other than preoperative 
anticholinergic load have a greater influence on the devel-
opment of POD. Future analyses should also examine the 
influence of intra- and postoperative administration of 
anticholinergic drugs.
A key strength of this study is the prospective multicenter 
design. POD was characterized by a comprehensive, stand-
ardized and validated assessment according to current rec-
ommendations. The study database contains further informa-
tion on possible confounders, and we were able to investigate 
the associations over a wide range of surgical disciplines, 
reflecting the setting conditions that apply to routine preop-
erative risk evaluation.
Nevertheless, some important limitations must be consid-
ered. The application of further anticholinergic scales and 
the consideration of interactions, including dosages, could 
have provided further insight. A criterion of the parent Bio-
Cog study excluded patients with severe preoperative cogni-
tive deficits, although they are known to have a very high 
risk of developing POD. Although the incidence of POD 
would probably have been higher if these patients had been 
included, we do not know whether there would have been an 
association with preoperative anticholinergic load and POD.
5  Conclusion
Our analysis found no association between preoperative 
anticholinergic load (according to the ADS, ARS and ACBS) 
and the development of POD in older surgical patients. 
Future analyses should examine the influence of intra- and 
postoperative administration of anticholinergic drugs as well 
as dosages of and interactions between medications.
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